Levetiracetam in Dogs: Crushing vs. Splitting ER Tablets

Crushing extended-release levetiracetam tablets in dogs alters how the drug enters the bloodstream, causing it to produce a higher peak drug level and wear off sooner than intact tablets. While splitting these tablets for smaller dogs appears to maintain the intended slow-release effect, crushing them eliminates the extended-release properties, as detailed in a study published online October 23, 2026, in the American Journal of Veterinary Research.

Levetiracetam is used for epilepsy treatment, and the extended-release version is designed to provide a steady therapeutic level over a 12-hour window. When that window is shattered by crushing the pill, the dog is exposed to a higher initial spike of the drug followed by a premature dip below the target therapeutic range.

Crushing eliminates the 12-hour window

The research team, led by A. Mondino and colleagues, tested 500-mg tablets to see how different administration methods affected pharmacokinetics. They found a contrast between splitting a pill and crushing it. Split tablets behaved similarly to intact ones, suggesting that splitting is a viable way to adjust dosages for smaller dogs without needing to switch to compounded formulations.

Crushed tablets, however, told a different story. When the tablets were crushed and administered as a suspension in water, they produced a higher peak drug level than intact tablets. More critically, the drug levels plummeted much faster. While intact and split tablets stayed above the target therapeutic level for nearly 11 hours, the crushed versions fell below that threshold at approximately 8.5 hours.

The myth of the split-tablet shortcut

The data suggests this is a misconception. The study found that split tablets did not peak any earlier or higher than intact tablets. Splitting the pill does not provide the rapid rise in drug levels needed to combat a cluster seizure. For those moments, the immediate-release form of levetiracetam is often prescribed because rapid absorption is preferred.

Interestingly, the researchers noted that crushed tablets reached peak levels at a time similar to what has previously been reported in dogs for immediate-release levetiracetam. This suggests that while crushing shouldn’t be the primary method of dosing, it might warrant further evaluation as an adjunct option during cluster seizures if the immediate-release version isn’t available.

The risk of compounded alternatives

Many veterinarians currently rely on compounded extended-release formulations to get the right dose for smaller breeds. However, these compounded versions are not FDA approved.

The lack of regulatory oversight for compounded drugs introduces variables that can compromise patient care, including:

Inconsistent drug strength across different batches.
Questions regarding the stability of the formulation.
General quality control and regulatory concerns that do not exist with manufacturer-approved tablets.

By proving that splitting a regulated tablet maintains its pharmacokinetic profile, the study suggests that clinicians can reduce their reliance on these compounded alternatives.

Critical gaps in the data

Despite the clear trends, the authors were careful to highlight the study’s boundaries. The research focused on a single extended-release product; because different generic manufacturers use different formulations, these results might not apply to every generic extended-release levetiracetam product without formulation-specific information or direct evaluation.

There are also practical variables that remain unknown. The dogs in the study were fasted, meaning it is unclear how a meal in the stomach would affect the absorption of a crushed versus an intact tablet. The study was not blinded, lacked a direct immediate-release comparison group, and was not designed to assess bioequivalence.

If the tablet is crushed, the “extended” part of the extended-release promise vanishes.

Keep reading